Elutia (ELUT) Stock Price, News & Analysis

Company Overview

Elutia Inc. is a medical technology company focused on developing and commercializing biologic and drug-eluting biomaterials for use with implantable medical devices. Its technologies are designed to support tissue integration, deliver therapeutic agents locally and help address complications associated with implanted devices, including infection and inflammation.

The company’s portfolio includes CanGaroo biologic envelopes, which are used to stabilize and protect certain cardiac implantable electronic devices while supporting incorporation into surrounding tissue. Elutia is also developing additional products based on its drug-eluting biomaterials platform, including bioresorbable technologies intended for applications in cardiovascular and other surgical procedures.

Elutia was formerly known as Aziyo Biologics and adopted its current name in 2023. The company is headquartered in Silver Spring, Maryland, and serves the medical-device and healthcare markets primarily through its commercial products and development programs.

Key Stats

• Today's Range: $0.76 to $0.80
• 50-Day Range: $0.78 to $1.01
• 52-Week Range: $0.50 to $1.39
• Volume: 20,612 shs
• Average Volume: 170,634 shs
• Market Capitalization: $35.03 million
• P/E Ratio: 0.83
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Elutia Stock Analysis - MarketRank™

Elutia scored higher than 24% of companies evaluated by MarketBeat, and ranked 808th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Elutia has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Elutia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elutia is 0.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elutia is 0.83, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.58.

Price to Book Value per Share Ratio

Elutia has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Elutia has been sold short.

Short Interest Ratio / Days to Cover

Elutia has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elutia has recently increased by 13.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elutia does not currently pay a dividend.

Dividend Growth

Elutia does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: N/A

News Sentiment

Elutia has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Elutia this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ELUT on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elutia insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Elutia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

74.03% of the stock of Elutia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ELUT
• CIK: 1708527
• Web: www.elutia.com
• Phone: (240) 247-1143
• Fax: 510-307-9896
• Employees: 180
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.95
• Trailing P/E Ratio: 0.83
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $53.38 million
• Net Margins: 426.93%
• Pretax Margin: -184.24%
• Return on Equity: -407.37%
• Return on Assets: -47.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.64

Sales & Book Value

• Annual Sales: $12.29 million
• Price / Sales: 2.85
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.65 per share
• Price / Book: 1.22

Miscellaneous

• Outstanding Shares: 44,290,000
• Free Float: 36,406,000
• Market Cap: $35.03 million
• Optionable: Not Optionable
• Beta: 0.84